Eliem Therapeutics is a biotechnology business based in the US. Eliem Therapeutics shares (ELYM) are listed on the NASDAQ and all prices are listed in US Dollars. Eliem Therapeutics employs 43 staff and has a market cap (total outstanding shares value) of 0.00.
Finder Award
SoFi Invest
tastyworks
| Latest market close | $3.62 |
|---|---|
| 52-week range | $2.36 - $11.51 |
| 50-day moving average | $3.07 |
| 200-day moving average | $3.64 |
| Wall St. target price | $6.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-2.54 |
*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $3.6239 from 2023-01-25
| 1 week (2023-01-20) | -5.63% |
|---|---|
| 1 month (2022-12-27) | 39.92% |
| 3 months (2022-10-27) | 19.60% |
| 6 months (2022-07-27) | 20.40% |
| 1 year (2022-01-27) | -55.86% |
|---|---|
| 2 years (2021-01-23) | N/A |
| 3 years (2020-01-23) | N/A |
| 5 years (2018-01-23) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -17.91% |
| Return on equity TTM | -30.88% |
| Profit margin | 0% |
| Book value | $5.06 |
| Market capitalisation | $103.3 million |
TTM: trailing 12 months
We're not expecting Eliem Therapeutics to pay a dividend over the next 12 months.
You may also wish to consider:
Eliem Therapeutics, Inc. , a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase IIa clinical trial; and ETX-155 for the treatment of major depressive disorder, perimenopausal depression, and focal onset seizures that is in Phase I clinical trial. The company also develops preclinical pipeline programs, such as Kv7 Program for pain, epilepsy, and depression; and Anxiolytic for the treatment of generalized anxiety disorder. Eliem Therapeutics, Inc. was incorporated in 2018 and is headquartered in Redmond, Washington. .
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Learn about stock analysis and how to use it to find the right company to buy.
